Amneal (AMRX) Q4 2025 earnings review
Strong 2025 Finish, But 2026 Guidance Reveals Hidden Segment Headwinds
Amneal delivered a robust Q4, with revenue accelerating 11% to $814M and Adjusted EPS surging to $0.21. The full-year results confirm the success of management's strategic diversification into complex generics and specialty brands. However, a deeper look at the 2026 guidance exposes significant structural shifts: while overall profitability is expanding, two of the company's three segments (Specialty and AvKARE) are guided to decelerate or contract sharply in 2026, forcing the Affordable Medicines segment to carry the top-line growth burden.
🐂 Bull Case
Adjusted EBITDA grew 13% in Q4 (faster than the 11% revenue growth) and 2026 guidance targets an 8% EBITDA boost on just ~3% revenue growth, proving Amneal is successfully scaling high-margin products while controlling costs.
The company continues to launch high-value non-oral solid generics and is advancing a rich biosimilar pipeline (including its 4th and 5th approvals and a XOLAIR biosimilar BLA), shifting the portfolio mix toward higher-barrier, stickier revenues.
🐻 Bear Case
Despite a massive 24% revenue surge in Q4, the AvKARE segment is guided to drop from $745M in 2025 to $625-$700M in 2026, severely dragging down overall corporate top-line growth.
Management heavily promoted CREXONT and BREKIYA uptake, yet 2026 Specialty revenue is guided entirely flat, meaning the upcoming RYTARY Loss of Exclusivity (LOE) is acting as a massive anchor offsetting all new brand gains.
⚖️ Verdict: ⚪
Neutral. The bottom-line leverage and debt-reduction story is fantastic, but the underlying 2026 revenue mix requires investors to accept shrinking legacy businesses (AvKARE, RYTARY) while banking heavily on 7-8% growth in Affordable Medicines to keep the top-line afloat.
Key Themes
Bottom-Line Leverage Accelerating
Amneal's pivot toward complex products and successful Q3 2025 debt refinancing is generating massive operating leverage. Adjusted EBITDA in Q4 hit $175M (+13% YoY), and GAAP Net Income swung from a $31M loss to a $35M profit. Moving into 2026, the company expects Adjusted EPS to grow roughly 18% at the midpoint, vastly outpacing top-line revenue growth.
The AvKARE Cliff
Reversing. In Q4, AvKARE was the fastest-growing major segment (+24% to $210.7M), driven by government label sales. But the narrative abruptly shifts in the 2026 guidance. Management expects AvKARE to generate $625M to $700M in 2026—a drastic 6% to 16% YoY decline from 2025's $744.7M. This breaks the pattern of long-term stability and implies lost contracts or severe distribution channel headwinds.
Specialty Narrative vs. Reality (RYTARY LOE)
Stagnating. The press release champions CREXONT's 'strong uptake' and the BREKIYA autoinjector launch. Indeed, Specialty Q4 revenue rocketed 38% YoY. However, 2026 guidance explicitly forecasts Specialty revenue to be 'flat year-over-year' (~$528M). This specific data point contradicts the bullish tone, indicating that the highly anticipated RYTARY generic entry (Loss of Exclusivity) will cannibalize the segment so heavily that it entirely neutralizes the growth of the new flagship products.
Affordable Medicines Pipeline Starts to Deliver
Accelerating. To offset the AvKARE and Specialty weaknesses in 2026, Amneal is relying heavily on its legacy Affordable Medicines segment, guiding for 7% to 8% growth in 2026. This confidence stems from a 'robust cadence' of new approvals, specifically their first two inhalation products and fourth/fifth biosimilars. As complex non-oral solids become a larger share of the pie, this segment's gross margin expanded from 40.0% to 41.8% (Non-GAAP) in FY25.
Macro Hedge: U.S. Manufacturing Footprint
Stable. In previous quarters, management highlighted their 'Made in America' strategy as a key competitive advantage. With ongoing geopolitical shifts and potential tariff impositions threatening offshore supply chains (specifically from China and India), Amneal's heavy U.S. manufacturing base positions them to secure domestic government contracts (via AvKARE) and avoid massive margin compression from import duties.
Affordable Medicines Q4 Dip
Decelerating. Despite the bullish full-year 2026 outlook, Affordable Medicines actually contracted 1% YoY in Q4 2025 to $436M. Management attributed this to 'the timing of revenue for key products and new launches.' Investors should monitor Q1 2026 closely to ensure this was genuinely a timing issue and not a sign of competitive pricing pressure in the complex generics market.
Other KPIs
Up 15% from $295 million in FY24. Amneal continues to demonstrate strong cash conversion. The 2026 guidance projects $325M-$375M, excluding discrete legal settlements, which provides ample runway for debt servicing and CapEx requirements.
Amneal finished 2025 with $2.69B in gross debt and $282M in cash. Following the massive Q3 2025 refinancing (extending maturities to 2032 via new Term Loans and Senior Notes), interest expense dropped in Q4 to $56M (from $61M). The net leverage ratio improved to 3.5x, down from 3.9x a year ago, achieving their sub-4x target well ahead of schedule.
Guidance
Decelerating. The midpoint of $3.10B implies roughly 2.7% YoY growth, a noticeable slowdown from the 8% growth achieved in 2025. This reflects the steep expected declines in the AvKARE segment and zero growth in Specialty.
Accelerating. The midpoint of $740M implies 7.5% YoY growth. Achieving 7.5% EBITDA growth on just 2.7% top-line growth demonstrates excellent cost control and a favorable product mix shift toward higher-margin complex generics.
Accelerating. Implies 18% YoY growth at the midpoint ($0.98 vs $0.83). Benefiting heavily from the 2025 debt refinancing which structurally lowered interest expenses, allowing operating income to flow cleanly to the bottom line.
Accelerating. Up from $89M in 2025. This likely reflects continued investments in complex manufacturing capabilities, potentially tied to their ongoing build-out for the GLP-1 (Metsera) collaboration and U.S. injectable footprint.
Key Questions
AvKARE Growth Collapse
AvKARE grew 24% in Q4, yet full-year 2026 guidance implies a YoY revenue decline of $45M to $120M for the segment. What specific contract losses, channel dynamics, or pricing pressures are driving this sharp reversal?
Specialty Segment Bridge
You are guiding for flat Specialty revenue in 2026. Can you explicitly bridge the expected revenue ramp from CREXONT and BREKIYA against the specific anticipated headwinds from the RYTARY Loss of Exclusivity?
Timing of Affordable Medicines Recovery
Affordable Medicines revenue fell 1% in Q4 due to 'timing'. What specific product launches slipped, and what is your confidence level that this revenue is fully recaptured in Q1 2026 to support your 7-8% annual growth target?
Biosimilar Vertical Integration
Management has previously expressed a desire to vertically integrate the biosimilar business. With net leverage now down to 3.5x, are you actively pursuing M&A to achieve this in 2026, or will cash be directed entirely to organic debt paydown?